This FcγRIIb-mediated internalization of rituximab was correlated with receptor expression in different subtypes of B cell lymphoma, such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), marginal zone lymphoma, follicular lymphoma (FL), and diffuse large B cell lymphoma [96,97]. This evidence concerns the gene FCGR2B and B-cell chronic lymphocytic leukemia.